Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Respiratory Medicines Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration. YUPELRI YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease....

Recent company news

TBPHTheravance Biopharma2026-06-29 10:00 EST

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

TBPHTheravance Biopharma2026-05-07 12:30 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-19 12:30 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-03 13:30 EST

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

TBPHTheravance Biopharma2025-11-20 16:00 EST

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

Stock data

Close: 16.92 USD
Market cap: 803.2M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Related news

Theravance Biopharma to Participate in Upcoming Investor Conferences

Savara to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27th

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference

Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026

Beyond Air to Participate in the D. Boral Capital Global Conference 2026

Beyond Air to Participate in the 38th Annual Roth Conference in March

Theravance Biopharma